Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Toxicity to reproduction
Some information in this page has been claimed confidential.
Administrative data
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- other: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Study period:
- From 2013, August 16 to 2014, April 2
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 014
- Report date:
- 2014
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- March 1996
- Deviations:
- yes
- Remarks:
- The study integrity was not adversely affected by the deviations.
- Principles of method if other than guideline:
- List of protocol deviations:
1. On Day 4 of lactation, no clinical observations were registered in the computer for pup 5 of litter 56 (Group 2).
Evaluation: Sufficient information available. Moreover, no findings were noted on Day 3 and 5, and its body weight was determined on Day 4.
2. Analysis of stability of the test substance under test conditions was not performed as part of this study, since Total Organic Carbon (TOC) analysis is a general method that does not distinguish original substance from hydrolysis product(s).
Evaluation: Data from the sponsor indicated stability in water for >24 hours at a concentration of 5%. As all formulations (2, 6 and 20%) were prepared daily within 4 hours prior to dosing, it can be assumed that the formulations under the current study conditions were also sufficiently stable.
3. Carbon analysis of formulations were recorded electronically using Shimadzu TOC-Control V version 2.10 (Shimadzu, Kyoto, Japan).
Evaluation: omission from the protocol. Appropriate method was used. - GLP compliance:
- yes (incl. QA statement)
- Limit test:
- yes
Test material
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Crl:WI(Han) (outbred, SPF-Quality
- Details on species / strain selection:
- This species and strain of rat has been recognized as appropriate for general and reproduction toxicity studies. The laboratory has general and reproduction/developmental historical data in this species from the same strain and source. This animal model has been proven to be susceptible to the effects of reproductive toxicants.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Test system Rat: Crl:WI(Han) (outbred, SPF-Quality). Nulliparous and non-pregnant females and untreated animals were used at initiation of the study.
Source F0: Charles River Deutschland, Sulzfeld, Germany.
Age at start F0-treatment: Approximately 11 weeks.
Number of F0-animals 40 females and 40 males.
Acclimatization F0: At least 5 days prior to start of treatment.
Health inspection F0: Upon receipt of the animals.
Randomization F0: Prior to commencement of treatment, by computer-generated random algorithm according to body weight, with all animals within ± 20% of the sex mean.
Identification F0: Earmark and tattoo.
Parturition: The females were allowed to litter normally. Day 1 of lactation was defined as the day when a litter was found completed (i.e. membranes and placentas cleaned up, nest build up and/or feeding of pups started). Females that were littering were left undisturbed.
Number of pups: 430 pups.
Identification of pups: On Day 1 of lactation, all pups were individually identified by means of subcutaneous injection of Indian ink.
Conditions: Environmental controls for the animal room were set to maintain 18 to 24°C, a relative humidity of 40 to 70%, approximately 15 room air changes/hour, and a 12-hour light/12-hour dark cycle. Any variations to these conditions were maintained in the raw data and had no effect on the outcome of the study.
Accommodation
Pre-mating: Animals were housed in groups of 5 animals/sex/cage in Macrolon plastic cages (MIV type, height 18 cm).
Mating: Females were caged together with males on a one-to-one-basis in Macrolon plastic cages (MIII type, height 18 cm).
Post-mating: Males were housed in their home cage (Macrolon plastic cages, MIV type, height 18 cm) with a maximum of 5 animals/cage. Females were individually housed in Macrolon plastic cages (MIII type, height 18 cm).
Lactation: Pups were kept with the dam until termination in Macrolon plastic cages (MIII type, height 18 cm). During locomotor activity monitoring of the dams the pups were kept warm in their home cage using bottles filled with warm water. In order to avoid hypothermia of pups, pups were not left without their dam or a bottle filled with warm water for longer than 30-40 minutes. General Sterilized sawdust as bedding material (Litalabo, S.P.P.S., Argenteuil, France) and paper as cage-enrichment/nesting material (Enviro-dri, Wm. Lillico & Son (Wonham Mill Ltd), Surrey, United Kingdom) were supplied. During locomotor activity monitoring, animals were housed individually in a Hi-temp polycarbonate cage (Ancare corp., USA; dimensions: 48.3 x 26.7 x 20.3 cm) without cage-enrichment, bedding material, food and water. Diet Free access to pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany).
Water: Free access to tap-water.
Diet, water, bedding and cage-enrichment/nesting material evaluation for contaminants and/or nutrients was performed according to facility standard procedures. There were no findings that could interfere with the study.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- Dose volume: 5 mL/kg body weight. Actual dose volumes were calculated according to the latest body weight.
- Details on mating procedure:
- Following a minimum of 14 days of exposure for the males and females, one female was cohabitated with one male of the same treatment group, avoiding sibling mating. Detection of mating was confirmed by evidence of sperm in the vaginal lavage or by the appearance of an intravaginal copulatory plug. This day was designated Day 0 post-coitum. Once mating occurred, the males and females were separated. Parturition: The females were allowed to litter normally. Day 1 of lactation was defined as the day when a litter was found completed (i.e. membranes and placentas cleaned up, nest build up and/or feeding of pups started).
Females that were littering were left undisturbed. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- As the validated method was not finalized yet, formulation samples were collected during in-life (31 October 2013) and stored in the freezer at ≤-15°C until analyses. However, as the NPOC method was not suited to measure the test substance in these frozen samples, additional samples were collected after the in-life phase (19 December 2013). These formulations were prepared in the same manner as used during the study. For quantitative analysis of the test substance in formulation, Total Organic Carbon (TOC) analysis was used (project 503334). Samples of formulations were analyzed for homogeneity (highest and lowest concentration) and accuracy of preparation (all concentrations). Stability could not be determined since TOC analysis is a general method that does not distinguish original substance from hydrolysis product(s); therefore results on stability assessment were not reported. Accuracy of preparation was considered acceptable if mean measured concentrations were 90-110% of target concentration. Homogeneity was demonstrated if the coefficient of variation was ≤ 10%.
- Duration of treatment / exposure:
- Males were exposed for 29 days, i.e. 2 weeks prior to mating, during mating, and up to the day prior to scheduled necropsy. Females were exposed for 41-47 days, i.e. during 2 weeks prior to mating, during mating, during post-coitum, and during at least 4 days of lactation (up to the day prior to scheduled necropsy). Female no. 47 (Group 1) was not dosed during littering.
- Frequency of treatment:
- Once daily for 7 days per week, approximately the same time each day with a maximum of 6 hours difference between the earliest and latest dose.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 300 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10 animal per sex per dose
- Control animals:
- yes, concurrent vehicle
Examinations
- Parental animals: Observations and examinations:
- Main observation and examinations have been described in the repeated-dose study.
General reproduction data: Male number paired with, mating date, confirmation of pregnancy, and delivery day were recorded. Pregnant females were examined to detect signs of difficult or prolonged parturition, and cage debris of pregnant females was examined to detect signs of abortion or premature birth. Any deficiencies in maternal care (such as inadequate construction or cleaning of the nest, pups left scattered and cold, physical abuse of pups or apparently inadequate lactation or feeding) were examined. - Oestrous cyclicity (parental animals):
- Not reported
- Sperm parameters (parental animals):
- From the selected 5 males of the control and high dose group, and all males suspected to be infertile, additional slides of the testes were prepared to examine staging of spermatogenesis. The testes were processed, sectioned at 3-4 micrometers, and stained with PAS/haematoxylin (Klinipath, Duiven, The Netherlands).
- Litter observations:
- Mortality / Viability: The numbers of live and dead pups on Day 1 of lactation and daily thereafter were determined. If possible, defects or cause of death were evaluated.
Clinical signs: At least once daily, detailed clinical observations were made for all animals.
Body weights: Live pups were weighed on Days 1 and 4 of lactation.
Sex: Sex was determined for all pups on Days 1 and 4 of lactation. - Postmortem examinations (offspring):
- Necropsy pups
Pups surviving to planned termination were killed by decapitation on Days 5-7 of lactation. All pups were sexed and descriptions of all external abnormalities were recorded. - Statistics:
- The following statistical methods were used to analyze the data:
- If the variables could be assumed to follow a normal distribution, the Dunnett-test based on a pooled variance estimate was applied for the comparison of the treated groups and the control groups for each sex.
- The Steel-test was applied if the data could not be assumed tofollow a normal distribution.
- The Fisher Exact-test was applied to frequency data.
- The Kruskal-Wallis nonparametric ANOVA test was applied to motor activity data to determine intergroup differences. In case intergroup differences were seen, the Wilcoxon test was applied to compare the treated groups to the control group.
All tests were two-sided and in all cases p < 0.05 was accepted as the lowest level of significance.
Group means were calculated for continuous data and medians were calculated for discrete data (scores) in the summary tables. Test statistics were calculated on the basis of exact values for means and pooled variances. Individual values, means and standard deviations may have been rounded off before printing. Therefore, two groups may display the same printed means for a given parameter, yet display different test statistics values. - Reproductive indices:
- For each group, the following calculations were performed:
Mating index (%)
Fertility index (%)
Conception index (%)
Gestation index (%)
Duration of gestation Number of days between confirmation of mating and the beginning of parturition - Offspring viability indices:
- Percentage live males at First Litter Check
Percentage live females at First Litter Check
Percentage of postnatal loss Number of dead pups before planned necropsy
Viability index
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No toxicologically significant clinical signs were noted during the observation period. Incidental findings that were noted included piloerection and rales. These findings occurred within the range of background findings to be expected for rats of this age and strain which are housed and treated under the conditions in this study. At the incidence observed, these were considered signs of no toxicological relevance.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No toxicologically relevant changes in body weights and body weight gain were noted. The statistically significant changes in body weight gain noted for males at 100 mg/kg were not considered toxicologically relevant as no dose response relationship was observed and the individual values were within normal limits.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Food consumption before or after allowance for body weight was similar between treated and control animals.
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- The statistically significantly decreased prothrombin time for males treated at 300 mg/kg was considered to be of no toxicological relevance as this occurred in the absence of a treatment-related distribution and remained within the range considered normal for rats of this age and strain.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Clinical biochemistry parameters of treated rats were considered not to have been affected by treatment up to 1000 mg/kg.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- Hearing ability, pupillary reflex, static righting reflex and grip strength were normal in all selected animals.
The variation in motor activity did not indicate a relation with treatment.
All groups showed a similar habituation profile with very high activity in the first interval that decreased over the duration of the test period.
The statistically significant increase noted for number of ambulations for males at 100 mg/kg was not considered toxicologically relevant as the individual values were within normal limits and no dose response relationship was seen. - Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Possible treatment-related findings were recorded in the heart of males and adrenal glands of females.
Heart, males:
- an increase in severity (slight degree) of mononuclear inflammation in 1/5 males treated at 1000 mg/kg, compared to minimal degrees in 1/5 males treated at 0 mg/kg, in 1/5 males at 100 mg/kg and in 1/5 males at 300 mg/kg.
- an increase in incidence and/or severity of myofiber degeneration (2/5, up to slight) in males treated at 1000 mg/kg, compared to minimal degree in 1/5 males treated at 300 mg/kg and absence of this finding in control males and males treated at 100 mg/kg.
Adrenal glands, females: an increase in incidence of vacuolation of the zona glomerulosa in 4/5 females treated at 1000 mg/kg, compared to 1/5 females treated at 0 mg/kg, 1/5 females at 100 mg/kg and 1/5 females at 300 mg/kg.
The remainder of microscopic findings recorded, were within the normal range of background pathology encountered in Wistar (Han) rats of this age. In each group one or two females were not pregnant. No treatment-related findings were recorded in
the reproductive organs of those females and their matching males. - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- no effects observed
- Description (incidence and severity):
- The spermatogenic staging profiles were normal for all males examined.
- Reproductive performance:
- no effects observed
Details on results (P0)
Mating, fertility and conception indices, precoital time, and number of corpora lutea and implantation sites were unaffected by treatment.
At 300 mg/kg, two females (nos. 63 and 70) had a relatively low number of corpora lutea, implantation sites and/or living pups at first litter check. As this was not noted at 1000 mg/kg and these low numbers are occasionally seen historically in control data, it was not considered toxicologically relevant.
No toxicologically relevant effects on gestation index and duration, parturition, maternal care and early postnatal pup development (mortality, clinical signs, body weight and macroscopy) were observed.
Parturition/maternal care
No signs of difficult or prolonged parturition were noted among the pregnant females.
Examination of cage debris of pregnant females revealed no signs of abortion or premature birth. No deficiencies in maternal care were observed.
Effect levels (P0)
- Dose descriptor:
- NOAEL
- Effect level:
- > 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Target system / organ toxicity (P0)
- Critical effects observed:
- no
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- Number of dead and living pups at first litter check, postnatal loss, viability index and sex ratio were unaffected by treatment, and clinical signs, body weight and external macroscopy did not reveal treatment-related findings. The statistically significantly change noted for sex ratio for pups at 300 mg/kg (71% female pups at 300 mg/kg compared to 52% female pups at the control group) was not considered toxicologically significant as this change was not noted at the higher dose of 1000 mg/kg.
Incidental findings of pups consisted of blue spot on several body parts and scabbing of the snout.
The nature and incidence of these findings remained within the range considered normal for pups of this age, and were therefore considered to be of no toxicological relevance. - Mortality / viability:
- no mortality observed
- Description (incidence and severity):
- Two pups at 100 mg/kg and one pup at 300 mg/kg were found dead or missing during lactation. Pups missing were most likely cannibalised. No toxicological relevance was attributed to these dead/missing pups since the mortality incidence did not show a dose-related trend and remained within the range considered normal for pups of this age.
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- not examined
Developmental neurotoxicity (F1)
- Behaviour (functional findings):
- not examined
Developmental immunotoxicity (F1)
- Developmental immunotoxicity:
- not examined
Effect levels (F1)
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- > 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Target system / organ toxicity (F1)
- Critical effects observed:
- no
Overall reproductive toxicity
- Reproductive effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- Parental NOAEL: 300 mg/kg for males, and at least 1000 mg/kg for females
Reproduction NOAEL: at least 1000 mg/kg
Developmental NOAEL: at least 1000 mg/kg - Executive summary:
The test material was administered by daily oral gavage to male and female Wistar Han rats at dose levels of 100, 300 and 1000 mg/kg. Males were exposed for 2 weeks prior to mating, during mating, and up to termination (for 29 days). The females were exposed for 2 weeks prior to mating, during mating, during post-coitum, and at least 4 days of lactation (for 41-47 days). Formulation analysis showed that the formulations were prepared accurately and homogenously.
Parental results: Parental toxicity was observed for males at 1000 mg/kg. This consisted of a subtle increase in severity of mononuclear inflammation and in incidence and/or severity of myofiber degeneration in the heart. Both findings were slightly above the range of background findings of Wistar (Han) rats of this age. Therefore a possible test item-related effect cannot be excluded.
For females at 1000 mg/kg, an increase in incidence of vacuolation of the zona glomerulosa of the adrenal glands was noted. However, based on the minimal degree and absence of other test item related findings in the females, this finding was considered not to be adverse.
At 1000 mg/kg, increased weights (absolute and relative) of seminal vesicles and uterus were noted. In addition, relative kidneys weights were higher for males treated at 300 and 1000 mg/kg. In the absence of corroborative findings in blood parameters and histopathological examination, these changes were not considered toxicologically significant. No treatment-related changes were noted in any of the remaining parental parameters investigated in this study (i.e. clinical appearance, functional observations, body weight, food consumption, clinical laboratory investigations, and macroscopic examination).
No reproduction toxicity was observed up to the highest dose level tested (1000 mg/kg).
No toxicologically relevant changes were noted in any of the reproductive parameters investigated in this study (i.e. mating, fertility and conception indices, precoital time, and numbers of corpora lutea and implantation sites).
Developmental results:
No developmental toxicity was observed up to the highest dose level tested (1000 mg/kg).
No toxicologically relevant changes were noted in any of the developmental parameters investigated in this study (i.e. gestation index and duration, parturition, maternal care and early postnatal pup development consisting of mortality, clinical signs, body weight and macroscopy).
In conclusion, treatment with the test subsatnce by oral gavage in male and female Wistar Han rats at dose levels of 100, 300 and 1000 mg/kg revealed parental toxicity for males at 1000 mg/kg. No reproduction and developmental toxicity was observed for treatment up to 1000 mg/kg.
Based on these results, the following No Observed Adverse Effect Levels (NOAEL) were derived:
Parental NOAEL: 300 mg/kg for males, and at least 1000 mg/kg for females
Reproduction NOAEL: at least 1000 mg/kg
Developmental NOAEL: at least 1000 mg/kg
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Nors ECHA internete skelbia daug informacijos jūsų kalba, dalis informacijos šiame puslapyje pateikiama tik anglų kalba. Daugiau apie ECHA daugiakalbystės politiką.
Sveiki atvykę į ECHA svetainę! Ši tinklavietė nepritaikyta naudoti su naršykle Internet Explorer 7 (ir ankstesnėmis jos versijomis). Jums reikalinga naujesnė naršyklės Internet Explorer versija.
Siekdami užtikrinti, kad būtų patogu naudotis mūsų svetaine, jos tinklapiuose naudojame slapukus.
Daugiau informacijos apie tai, kaip naudojame slapukus.